VanEck Associates’s PTC Therapeutics PTCT Stock Holding History

VanEck Associates’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,700	Closed	-$184K	–	1454
2026 Q1	$184K	Sell	2,700 -162	-6%	-$11.5K	﹤0.01%	1268
2025 Q4	$217K	Buy	+2,862	New	+$208K	﹤0.01%	1274

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

VanEck Associates's PTCT Position: Q2 2026 in Review

VanEck Associates sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 2,700 shares — an estimated $184K sold.

VanEck Associates first reported a position in PTCT in Q4 2025 and held it in 2 quarters. The position peaked at $217K in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

VanEck Associates reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
VanEck Associates sold 2,700 PTC Therapeutics shares in Q2 2026, an estimated $184K.
VanEck Associates first reported a position in PTC Therapeutics in Q4 2025 and held it in 2 quarters.
VanEck Associates's PTC Therapeutics position peaked at $217K in Q4 2025.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.